- About About
-
Medical
Medical
Medical Patient Resources Cannabis Care Certification Patient's Guide to Medical Cannabis Patient's Guide to CBD Talking to your doctor Become a Legal Medical Marijuana Patient The Medical Cannabis Patient’s Guide for U.S. Travel Guide to Using Medical Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Arthritis and Medical Cannabis Cancer and Medical Cannabis Chronic Pain and Medical Cannabis Gastrointestinal Disorders and Medical Cannabis HIV/AIDS and Medical Cannabis Movement Disorders and Medical Cannabis Multiple Sclerosis and Medical Cannabis Aging and Medical Cannabis Veterans and Medical Cannabis Medical Marijuana Conditions in Your Area Growing Cannabis Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources Medical Cannabis Continuing Medical Education (CME) Cannabis Safety Medical Cannabis Research
- Legal Legal
-
Advocacy
Advocacy
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
-
Policy
Policy
Policy Policy Positions Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Data Quality Act Briefs Fact Sheet on ASA's Data Quality Act Petition to HHS ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2021 State of the States Cannabis and Cannabis Resin- Critical Review Preparation Document Medical Cannabis in America
- News News
- Join Join
-
-
Deadline March 14, 2019 -- ASA Urges You to Submit Your Comments to FDA for International Rescheduling of Cannabis
The Food and Drug Administration (FDA) is collecting comments from you to help the United States shape its position on rescheduling cannabis during an upcoming United Nations meeting. The deadline for submissions is 11:59 p.m. on March 14, 2019. To make a comment, please click here. If you choose to submit a PDF, please make sure you reference FDA-2019-N-0767 in your comments.
These comments will directly impact how the United States responds to the World Health Organization’s recent recommendation regarding the rescheduling of cannabis under international law. Specifically, the World Health Organization is recommending that cannabis and cannabis resin be removed from Schedule IV of the 1961 Single Convention on Narcotic Drugs and that THC and its isomers be moved from the 1971 Convention on Psychotropic Substances to join cannabis in Schedule I of the Single Convention.
Schedule IV is the most restrictive classification for substances controlled under international treaties. It is reserved for substances that have the characteristics of being liable to abuse, produce ill effects, and are not suitable for medical treatment. Removing cannabis from Schedule IV of the Single Convention will signal that the international community recognizes the medicinal potential of cannabis and its derivatives.
Please take some time to make your voices heard through the Federal Register today!
Share